ADMA Biologics Faces Securities Fraud Lawsuit After Stock Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Source: PRnewswire
- Stock Price Plunge: ADMA Biologics' stock plummeted 29% due to allegations of channel stuffing by Culper Research, resulting in significant investor losses and potential violations of federal securities laws.
- Lawsuit Details: Bleichmar Fonti & Auld LLP has filed a class action lawsuit on behalf of ADMA investors, with a deadline of August 10, 2026, for investors to apply to lead the case, which is pending in the U.S. District Court for New Jersey under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Financial Impact: The report from Culper Research indicated that without the alleged channel stuffing, ADMA would have faced a 3% revenue decline in 2025 instead of the reported 20% growth, leading to stock price declines of 16.6% and 15% on March 24 and 25, respectively.
- Legal Consequences: The securities fraud allegations against ADMA could result in substantial damages and may affect its future financing capabilities and market reputation, further intensifying investor concerns regarding the transparency of its management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Securities Fraud Lawsuit After Stock Plunge
- Stock Price Plunge: ADMA Biologics' stock plummeted 29% due to allegations of channel stuffing by Culper Research, resulting in significant investor losses and potential violations of federal securities laws.
- Lawsuit Details: Bleichmar Fonti & Auld LLP has filed a class action lawsuit on behalf of ADMA investors, with a deadline of August 10, 2026, for investors to apply to lead the case, which is pending in the U.S. District Court for New Jersey under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Financial Impact: The report from Culper Research indicated that without the alleged channel stuffing, ADMA would have faced a 3% revenue decline in 2025 instead of the reported 20% growth, leading to stock price declines of 16.6% and 15% on March 24 and 25, respectively.
- Legal Consequences: The securities fraud allegations against ADMA could result in substantial damages and may affect its future financing capabilities and market reputation, further intensifying investor concerns regarding the transparency of its management.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ADMA Biologics on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false statements that undermined investor confidence.
- Allegation Details: The lawsuit claims that ADMA Biologics engaged in undisclosed related party transactions, utilized channel stuffing to inflate revenue, and lacked adequate internal controls, resulting in misleading positive statements about the company's business prospects, which could significantly impact stock prices.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, alleging channel stuffing, ADMA Biologics' stock price fell by 29.1% over two trading days, closing at $9.63 per share, reflecting market concerns over the company's financial health.
- Investor Action: ADMA Biologics investors have until August 10, 2026, to apply for lead plaintiff status in the class action, representing all investors in the litigation, indicating a growing concern over corporate governance and transparency that may influence future investment decisions.
See More
Multiple Companies Face Class Action Lawsuits
- BitGo Lawsuit Overview: BitGo Holdings, Inc. is facing allegations for failing to disclose the impact of declining digital asset prices on its financial performance during the class period from January 22 to May 13, 2026, with a lead plaintiff deadline set for August 7, 2026, potentially undermining investor confidence in its financial outlook.
- Via Transportation Allegations: Via Transportation, Inc. is accused of not disclosing a decline in annual recurring revenue per customer and existing regulatory issues that could hinder its expansion strategy in Germany during its September 2025 IPO, with a lead plaintiff deadline of August 10, 2026, which may affect investor sentiment.
- Zillow Legal Risks: Zillow Group, Inc. is under scrutiny for allegedly misrepresenting its agreement with Redfin as a partnership rather than an acquisition, which heightened its risk of regulatory scrutiny under antitrust laws during the class period from February 11, 2025, to May 7, 2026, with a lead plaintiff deadline of August 10, 2026, potentially impacting its market reputation.
- ADMA Related Party Transactions: ADMA Biologics, Inc. faces allegations of undisclosed related party transactions and revenue manipulation from August 9, 2024, to March 25, 2026, with a lead plaintiff deadline of August 10, 2026, raising significant concerns about its internal controls and investor trust.
See More
ADMA Biologics Faces Allegations of Financial Misconduct
- Allegations of Financial Misconduct: ADMA Biologics is accused of channel stuffing to misrepresent a 3% revenue decline as a 20% growth, leading to significant investor losses and highlighting severe transparency issues within the company.
- Independent Research Unveils Truth: A report by Culper Research indicates that ADMA's ASCENIV revenues actually declined by 3% in 2025, contradicting the reported 20% growth, revealing a critical disconnect between the company and its distributors.
- Legal Action Initiated: A securities class action has been launched on behalf of investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, with a deadline for claims set for August 10, 2026, likely impacting the company's stock price negatively.
- Market Confidence Eroded: The significant discrepancy between ADMA's financial reports and independent research findings has severely undermined investor trust, potentially leading to substantial stock price volatility and affecting future fundraising capabilities.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: ADMA Biologics, Inc. (NASDAQ: ADMA) faces a class action lawsuit for securities fraud covering the period from August 9, 2024, to March 25, 2026, alleging significant misstatements and omissions in financial reporting that undermine investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which misled investors about the company's business prospects and could have long-term negative impacts on stock prices.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations to ensure legal rights are protected.
See More
Faruqi & Faruqi Investigates ADMA Biologics Securities Fraud
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating ADMA Biologics for potential violations of federal securities laws between August 9, 2024, and March 25, 2026, involving undisclosed related-party transactions and false revenue reporting, which could lead to significant investor losses.
- False Statements Exposed: A report by Culper Research revealed that ADMA Biologics allegedly engaged in channel stuffing to inflate revenue, with actual growth in 2025 being -3% instead of the reported 20%, damaging the company's reputation and triggering a crisis of investor confidence.
- Stock Price Volatility: This news caused ADMA Biologics' stock price to plummet by 29% over two days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, reflecting market concerns about the company's financial health.
- Investor Action Call: Faruq & Faruqi LLP encourages investors who purchased ADMA Biologics securities during the specified period to contact them to discuss their legal rights and potential participation in a class action lawsuit before the August 10, 2026 deadline.
See More
ADMA Biologics Faces Securities Fraud Lawsuit After Stock Plunge
- Stock Price Plunge: ADMA Biologics' stock plummeted 29% due to allegations of channel stuffing by Culper Research, resulting in significant investor losses and potential violations of federal securities laws.
- Lawsuit Details: Bleichmar Fonti & Auld LLP has filed a class action lawsuit on behalf of ADMA investors, with a deadline of August 10, 2026, for investors to apply to lead the case, which is pending in the U.S. District Court for New Jersey under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Financial Impact: The report from Culper Research indicated that without the alleged channel stuffing, ADMA would have faced a 3% revenue decline in 2025 instead of the reported 20% growth, leading to stock price declines of 16.6% and 15% on March 24 and 25, respectively.
- Legal Consequences: The securities fraud allegations against ADMA could result in substantial damages and may affect its future financing capabilities and market reputation, further intensifying investor concerns regarding the transparency of its management.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ADMA Biologics on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false statements that undermined investor confidence.
- Allegation Details: The lawsuit claims that ADMA Biologics engaged in undisclosed related party transactions, utilized channel stuffing to inflate revenue, and lacked adequate internal controls, resulting in misleading positive statements about the company's business prospects, which could significantly impact stock prices.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, alleging channel stuffing, ADMA Biologics' stock price fell by 29.1% over two trading days, closing at $9.63 per share, reflecting market concerns over the company's financial health.
- Investor Action: ADMA Biologics investors have until August 10, 2026, to apply for lead plaintiff status in the class action, representing all investors in the litigation, indicating a growing concern over corporate governance and transparency that may influence future investment decisions.
See More
Multiple Companies Face Class Action Lawsuits
- BitGo Lawsuit Overview: BitGo Holdings, Inc. is facing allegations for failing to disclose the impact of declining digital asset prices on its financial performance during the class period from January 22 to May 13, 2026, with a lead plaintiff deadline set for August 7, 2026, potentially undermining investor confidence in its financial outlook.
- Via Transportation Allegations: Via Transportation, Inc. is accused of not disclosing a decline in annual recurring revenue per customer and existing regulatory issues that could hinder its expansion strategy in Germany during its September 2025 IPO, with a lead plaintiff deadline of August 10, 2026, which may affect investor sentiment.
- Zillow Legal Risks: Zillow Group, Inc. is under scrutiny for allegedly misrepresenting its agreement with Redfin as a partnership rather than an acquisition, which heightened its risk of regulatory scrutiny under antitrust laws during the class period from February 11, 2025, to May 7, 2026, with a lead plaintiff deadline of August 10, 2026, potentially impacting its market reputation.
- ADMA Related Party Transactions: ADMA Biologics, Inc. faces allegations of undisclosed related party transactions and revenue manipulation from August 9, 2024, to March 25, 2026, with a lead plaintiff deadline of August 10, 2026, raising significant concerns about its internal controls and investor trust.
See More
ADMA Biologics Faces Allegations of Financial Misconduct
- Allegations of Financial Misconduct: ADMA Biologics is accused of channel stuffing to misrepresent a 3% revenue decline as a 20% growth, leading to significant investor losses and highlighting severe transparency issues within the company.
- Independent Research Unveils Truth: A report by Culper Research indicates that ADMA's ASCENIV revenues actually declined by 3% in 2025, contradicting the reported 20% growth, revealing a critical disconnect between the company and its distributors.
- Legal Action Initiated: A securities class action has been launched on behalf of investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, with a deadline for claims set for August 10, 2026, likely impacting the company's stock price negatively.
- Market Confidence Eroded: The significant discrepancy between ADMA's financial reports and independent research findings has severely undermined investor trust, potentially leading to substantial stock price volatility and affecting future fundraising capabilities.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: ADMA Biologics, Inc. (NASDAQ: ADMA) faces a class action lawsuit for securities fraud covering the period from August 9, 2024, to March 25, 2026, alleging significant misstatements and omissions in financial reporting that undermine investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which misled investors about the company's business prospects and could have long-term negative impacts on stock prices.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations to ensure legal rights are protected.
See More
Faruqi & Faruqi Investigates ADMA Biologics Securities Fraud
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating ADMA Biologics for potential violations of federal securities laws between August 9, 2024, and March 25, 2026, involving undisclosed related-party transactions and false revenue reporting, which could lead to significant investor losses.
- False Statements Exposed: A report by Culper Research revealed that ADMA Biologics allegedly engaged in channel stuffing to inflate revenue, with actual growth in 2025 being -3% instead of the reported 20%, damaging the company's reputation and triggering a crisis of investor confidence.
- Stock Price Volatility: This news caused ADMA Biologics' stock price to plummet by 29% over two days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, reflecting market concerns about the company's financial health.
- Investor Action Call: Faruq & Faruqi LLP encourages investors who purchased ADMA Biologics securities during the specified period to contact them to discuss their legal rights and potential participation in a class action lawsuit before the August 10, 2026 deadline.
See More
